Categories
Change Password!
Reset Password!
A retrospective study was conducted to explore whether the new sequential therapy containing bismuth is effective to treat H.pylori infection in children.
A new sequential
therapy including bismuth for 14 days can be used as first-line therapy in
children as it offers a high rate of Helicobacter pylori (H. pylori)
elimination.
A retrospective study was conducted to explore whether the
new sequential therapy containing bismuth is effective to treat H.pylori
infection in children.
In this study, 75 patients (more than eight years of age, mean age 15.1 ± 2.4 years) suffering from H. pylori gastritis were included. As per Rome IV criteria, 38 subjects had dyspepsia and functional abdominal pain, and 37 subjects had alarm findings depicting organic disease.
Participants were treated with a new sequential therapy consisting of
lansoprazole, amoxicillin for seven days. This was subsequently followed by
lansoprazole, metronidazole, tetracycline, and bismuth subsalicylate. The
eradication status was estimated by the H. pylori stool antigen test eight
weeks after completion of the therapy.
No participant discontinued treatment due to adverse
effects. All participants had antral gastritis (76.0%) or pangastritis (24.0%).
The peptic ulcer rate was about 6.6%. Eradication therapy was administered to
all patients with or without peptic ulcer. The elimination of H pylori
eradication was attained in 69 (92.0%) patients and symptoms improved in 61 (81%)
of those eradicated patients.
In children, a new sequential therapy including bismuth for
14 days is a promising therapeutic approach to treat H. pylori infection.
Helicobacter
Efficacy of a novel sequential treatment regimen containing bismuth for Helicobacter pylori eradication in Turkish children
Melike Arslan et al.
Comments (0)